Intelligent Bio Solutions

Intelligent Bio Solutions Cash Conversion

The Cash Conversion Rate (OCF/Net Income) of Intelligent Bio Solutions (INBS) as of Oct 22, 2026 is 95.95 %. In the previous year, Cash Conversion Rate (OCF/Net Income) was 91.57 % — a change of 4.79% (higher).

Cash Conversion

95.95 %

YoY

4.79%

Last updated:

Cash Conversion Rate (OCF/Net Income) of Intelligent Bio Solutions is 2026 95.95 % . Cash Conversion Rate (OCF/Net Income) of Intelligent Bio Solutions was 2025 91.57 % . It decreases by 4.79% higher compared to the previous year.

The Intelligent Bio Solutions Cash Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion
Date
Cash Conversion
Jan 1, 2019
76.02 USD
Jan 1, 2020
13.43 USD
Jan 1, 2021
160.52 USD
Jan 1, 2022
40.43 USD
Jan 1, 2023
69.39 USD
Jan 1, 2024
94.24 USD
Jan 1, 2025
91.57 USD
Jan 1, 2026
95.95 USD
The Intelligent Bio Solutions Cash Conversion history
YEARCash ConversionYoY
95.95 %+4.79%
91.57 %-2.84%
94.24 %+35.81%
69.39 %+71.64%
40.43 %-74.81%
160.52 %+1,095.68%
13.43 %-82.34%
76.02 %-29.13%
107.26 %+49.53%
71.73 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Intelligent Bio Solutions Stock analysis

What does Intelligent Bio Solutions do? Intelligent Bio Solutions, Inc. generates revenue through its Commercially available Intelligent Fingerprinting Products (IFPG) segment, which includes a portable drug screening system analyzing fingerprint sweat via a one-time cartridge and handheld reader. The company also develops diagnostic tests under the Development Stage Saliva Glucose Biosensor Platform (SGBP), targeting diabetic patients with a non-invasive saliva glucose biosensor (SGB) intended to replace finger-prick blood monitoring. Its biosensor platform supports multiple biological analyte detection for point-of-care diagnostic tests (POCT) in clinical chemistry, immunology, tumor markers, allergens, and endocrinology. The firm serves primary health practitioners and patients seeking non-invasive monitoring solutions. The company's product portfolio features the IFPG segment's portable drug screening system, which is sold to healthcare providers and law enforcement agencies for rapid drug testing. The SGBP segment focuses on developing the Saliva Glucose Biosensor (SGB), a point-of-care diagnostic test expected to address the needs of diabetic patients requiring frequent glucose monitoring without invasive procedures. The biosensor platform enables detection of multiple analytes, expanding the company's offerings in clinical chemistry and related diagnostic fields. Intelligent Bio Solutions, Inc. targets primary health practitioners and patients as key segments for its non-invasive diagnostic solutions. The IFPG segment's portable drug screening system is designed for use in clinical and law enforcement settings, while the SGBP segment's Saliva Glucose Biosensor aims to provide a convenient alternative to traditional blood glucose monitoring for diabetic patients. The company's development stage products focus on replacing invasive methods with real-time, non-invasive monitoring technologies. Intelligent Bio Solutions is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Intelligent Bio Solutions stock

Cash Conversion Rate (OCF/Net Income) of Intelligent Bio Solutions is 95.95 % in 2026.

Cash Conversion Rate (OCF/Net Income) of Intelligent Bio Solutions changed from 91.57 % to 95.95 %, representing a 4.79% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Rate (OCF/Net Income) Intelligent Bio Solutions since 2006 – with annual values, charts, and detailed analysis.

Cash conversion measures how effectively net income converts to operating cash flow. Ratios above 100% indicate high-quality, cash-backed earnings.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Rate (OCF/Net Income)'s Intelligent Bio Solutions with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Rate (OCF/Net Income)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Rate (OCF/Net Income).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Intelligent Bio Solutions

All Key Metrics — Intelligent Bio Solutions